Valeant Pharmaceuticals International Inc. (NYSE: VRX) CEOÂ J. Michael Pearson has returned from sick leave. It is a wonder the board has accepted him back, based on what has happened to the pharmaceuticals company this…
Investors really took to BioMarin Pharmaceuticals stock and there was a favorable jump after the fourth-quarter earnings report.
Over the past week, Valeant Pharmaceuticals and a few other biotech companies made impressive runs, due to positive trial results and an FDA meeting.
Eight hours of sleep. That is the rule most often mentioned as the measure of a good night’s sleep. Some people claim they can get by on less, and for a few, much less.…
Syndax Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Peregine Pharmaceuticals has announced that it is discontinuing its Phase 3 Sunrise trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer.
Here are two big biopharmas, both with multibillion dollar portfolios and both of which have lost a combined $113 billion in market cap since August.
Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four of the largest names within the biotech space.
The February 12 short interest data have been compared with the previous report, and short interest increased across the board in these selected biotech stocks.
The February 12 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
Pfizer has announced that the FDA approved Xeljanz XR (tofacitinib citrate) extended-release tablets for the once-daily treatment of moderate to severe rheumatoid arthritis in certain patients.
PTC Therapeutics said that it has received a Refuse to File letter from the FDA regarding its New Drug Application for Translarna (ataluren).
In a new research report, Jefferies shuffles some of the pharmaceutical stocks in its coverage universe and a beaten-down dividend leader is now the top pick globally.
Trevena charged after the FDA granted a Breakthrough Therapy designation to its lead product candidate for the management of acute pain.
Allergan reported better-than-expected fourth-quarter financial results before the markets opened on Monday.
